ITMCTR2100004629RecruitingPhase 4
Real world research for Pingxiao capsule to treat triple negative breast cancer research
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Ages
- 18 to 75 (—)
- Sex
- Female
Inclusion Criteria
- •1. Triple negative breast cancer confirmed by histology or cytology;
- •2. The patients agreed to be treated;
- •3. They were 18-75 years old;
- •4. The expected survival time was more than 12 weeks;
- •5. ECoG status score was 0-2;
- •6. According to RECIST 1.1, there was at least one measurable lesion;
- •7. The organ function level must meet the following requirements:
- •Hematological indexes: absolute neutrophil count >= 1.5 x 10^9 / L, platelet count >= 80 x 10^9 / L, hemoglobin >= 9.0 g / dl (can be maintained by blood transfusion);
- •Liver function: total bilirubin <= 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase <= 2.5 times the upper limit of normal value, if there is intrahepatic transaminase <= 5 times the upper limit of normal value;
- •Renal function: creatinine <= 1.25 times the upper limit of normal value, and creatinine clearance rate >= 60ml / min;
- •8. Women of childbearing age must have urine pregnancy test within 7 days before treatment, and the result is negative, and they are not in lactation
- •During the lactation period, the male should agree to use appropriate contraceptive methods or have undergone surgical sterilization during the trial period and within 8 weeks after the last administration of the trial drug;
- •9. Ability to comply with research and follow-up procedures;
- •10. Patients have the ability to understand and sign informed consent voluntarily.
Exclusion Criteria
- •Subjects who meet any of the following exclusion criteria are not eligible to participate in the study:
- •1. Patients who have had any systemic anti-cancer treatment, including cytotoxic drug therapy, targeted drug therapy, experimental treatment, adjuvant chemotherapy or neoadjuvant chemotherapy (but patients with recurrence after stopping for more than 6 months can be selected);
- •2. The target focus was treated by radiotherapy or radio frequency;
- •3. Combination of phenytoin, carbamazepine, rifampin, barbital or St. John's grass;
- •4. Other malignant tumors have been developed in the past 5 years, except for the cured basal cell carcinoma, cervical in situ cancer, surgical treatment of localized prostate cancer or surgical resection of breast duct carcinoma in situ;
- •5. The patient has one or more of the following conditions:
- •Patients with symptomatic central nervous system metastasis or spinal cord compression;
- •A large number of pleural effusion or pericardial effusion;
- •Any unstable systemic disease (including active infection, poor control of hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic diseases);
- •It is impossible to accept oral administration, need high energy nutrition in vein, and have performed operations and activities that have previously affected absorption;
- •Patients with peptic ulcer and chronic diarrhea;
- •It is known that it is allergic to relevant components of Pingxiao capsule;
- •6. The researchers believe that subjects may not be able to complete the study or may not comply with the requirements of the study (for management reasons or other reasons).
Investigators
Similar Trials
Not yet recruiting
Phase 4
ingmitai capsule for the treatment of chronic prostatitisChronic ProstatitisITMCTR2000003084Peking University First Hospital
Recruiting
Phase 1
Real world clinical study of Liushen capsule in the treatment of pharyngitis and tonsillitispharyngitis, amygdalitisITMCTR2100004400The First Tianjin Medical University General Hospital, Affiliated Hospital of Guangzhou University of traditional Chinese Medicine
Not yet recruiting
Not Applicable
Prospective clinical study of Jintiange capsule in the treatment of osteosarcopeniasarcopenia and osteoporosisITMCTR2200006637The Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Recruiting
Phase 4
A randomized controlled trial of Naoxintong Capsule to reduce major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS)Acute coronary syndromeITMCTR2000003509The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Recruiting
Phase 4
Efficacy and safety of Wuling capsule in the treatment of early Parkinson's disease with mild depression: a multicenter, randomized, double-blind, placebo-controlled studyParkinson's diseaseITMCTR2100004821Xinhua Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine